Analyst Ratings For NASDAQ:ARCT – Arcturus Therapeutics (NASDAQ:ARCT)
Today, NASDAQ:ARCT – Arcturus Therapeutics (NASDAQ:ARCT) stock received an upgrade by WBB Securities from Hold ➝ Buy.
Some recent analyst ratings include
- 6/11/2018-WBB Securities Upgrade from a “Hold ➝ Buy” rating to a “” rating.
- 5/31/2018-LADENBURG THALM/SH SH Upgrade from a “Neutral ➝ Buy” rating to a “” rating.
- 1/22/2018-Chardan Capital initiated coverage with a Buy ➝ Buy rating.
- 9/29/2017-Roth Capital was Downgraded by analysts at Roth Capital from a “Buy ➝ Neutral” rating to a “” rating. They now have a $4.00 ➝ $1.00 price target on the stock.
- 6/12/2017-Jefferies Financial Group Reiterated Rating of Hold.
- 4/13/2017-Cantor Fitzgerald Reiterated Rating of Hold.
Recent Trading Activity for NASDAQ:ARCT – Arcturus Therapeutics (NASDAQ:ARCT)
Shares of NASDAQ:ARCT – Arcturus Therapeutics closed the previous trading session at 8.27 up +0.73 9.68% with shares trading hands.